Processa Pharmaceuticals, Inc. Advance Payments Netted Against Claim Receivable
Processa Pharmaceuticals, Inc. (PCSA) had Advance Payments Netted Against Claim Receivable of $155.50 thousand as of 2013-12-31, per its 10-K filed 2015-04-14.
Discontinued › Notes
us-gaap:AdvancePaymentsNettedAgainstClaimReceivable · last filed 2015-04-14
- 2013-12-31: Advance Payments Netted Against Claim Receivable $155.50K.
| Period end | Advance Payments Netted Against Claim Receivable |
|---|---|
| 2013-12-31 | $155.50K 10-K · filed 2015-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |